Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Table 3 Impact of clinicopathological parameters, including performance status and LINE-1 methylation status, on cancer recurrence in stage III or high-risk stage II CRCs (n = 336), assessed by univariate and multivariate Cox regression analyses

Parameters	Univariate analysis			Multivariate analysis
Parameters	HR	95 % C.I.	P ^a	HR	95 % C.I.	P ^a
Gender (male vs. female)	1.66	0.834–3.321	0.149
Age (≥60 years vs. <60 years)	1.45	0.774–2.719	0.245
BMI (overweight vs. normal)	1.29	0.674–2.454	0.445
Tumor location (distal vs. proximal)	1.94	0.897–4.205	0.092
Pathology (mucinous vs. non-mucinous)	1.29	0.311–5.343	0.726
Differentiation (high grade vs. low grade)	1.15	0.353–3.718	0.821
T stage (T4 vs. T1, 2, 3)	2.41	1.179–4.908	0.016	2.33	1.142–4.761	0.020
N stage (N 2 vs. N0, 1)	2.51	1.355–4.654	0.003	2.46	1.328–4.569	0.004
Microsatellite status (MSI-H vs. MSS + MSI-L)	1.24	0.381–4.002	0.725
Performance status (PS ≥ 1 vs. PS = 0)	1.46	0.766–2.770	0.251
LINE-1 methylation (low vs. high)	2.15	0.984–4.701	0.055

BMI body mass index, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, PS performance status
^aCox proportional hazard regression model, adjusted for other selected covariates

ISSN: 1868-7083